| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 65.00 | 89.1% | 466.2% |
| Total Income | 65.00 | 89.1% | 466.2% |
| Expenditure | 140.61 | 18.6% | 46.4% |
| PBT | — | ||
| Net Profit | -61.21 | 11.6% | 20.1% |
| OPM | — | ||
| NPM | -94.17% | ||
| EPS | -0.62 | 12.7% | 34.7% |
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05 Aug 2026 · 5 Aug, 4:46 pm
Summary
Kymera Therapeutics reported its financial results for the second quarter ended June 30, 2026, highlighting significant collaboration revenues of $65.0 million, up from $11.5 million in the prior year, largely due to milestone payments from Gilead Sciences and Sanofi. Research and development expenses rose to $119.5 million, reflecting increased investment in its pipeline, while the net loss narrowed to $61.2 million from $76.6 million in the same period last year. The company maintains a strong cash position of $1.5 billion, with a projected runway into 2029. Key business updates include the ahead-of-schedule completion of enrollment for the KT-621 BROADEN2 Phase 2b trial in atopic dermatitis, with data anticipated by year-end 2026.
Key Highlights
- 1
Kymera Therapeutics announced its financial results for the second quarter ended June 30, 2026.
- 2
Collaboration revenues were $65.0 million for the second quarter of 2026, significantly up from $11.5 million for the second quarter of 2025, driven by milestone payments.
- 3
Research and development expenses increased to $119.5 million for Q2 2026 from $78.4 million in Q2 2025, reflecting increased investment in the STAT6 program and platform.
- 4
General and administrative expenses were $21.1 million for Q2 2026, an increase from $17.6 million in Q2 2025, due to higher legal and professional service fees.
- 5
Net loss for the second quarter of 2026 was $61.2 million, an improvement from a net loss of $76.6 million for the second quarter of 2025.
- 6
The company ended the quarter with $1.5 billion in cash, cash equivalents, and investments, providing a runway into 2029.
- 7
Enrollment was completed in the KT-621 BROADEN2 Phase 2b AD trial nearly six months ahead of schedule, with data expected by year-end 2026.
Management Comments
Nello Mainolfi
Kymera is delivering in a pivotal period of execution, with multiple clinical-stage programs advancing, important data catalysts ahead, and growing conviction in the potential of oral degrader medicines to transform the standard of care for chronic, debilitating immunological diseases. The rapid completion of enrollment in our KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of our original timeline is a powerful example of the immense interest from clinicians and patients in a once-daily oral therapy and excellent execution from the Kymera team. The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options. We see the significant gaps that remain across the immunology treatment landscape, and we are hearing directly from clinicians, advocacy groups, patients and their families about the need for effective, safe, and convenient approaches. We remain focused on executing across our differentiated portfolio to address those needs. With KT-621 advancing in both AD and asthma, KT-579 progressing toward Phase 1 data and a planned patient proof-of-concept trial in lupus, and important progress across our partnered programs and early discovery engine, we are translating that urgency into action as we work to deliver a new generation of oral medicines.
Informational and educational content only. Not investment advice.